Simultaneous expression of flotillin-1, flotillin-2, stomatin and caveolin-1 in non-small cell lung cancer and soft tissue sarcomas

Abstract

BackgroundAt the present time, there is a lack of data about the involvement of flotillins and stomatin in the development of non-small cell lung cancer (NSCLC) and soft tissue sarcomas (STS). Moreover, changes in expression of members of different families of the microdomain-forming proteins (caveolins and SPFH-domain containing family) are usually investigated independently of each other. In this study we performed a combined analysis of flotillins, stomatin, and caveolin-1 expression in these pathologies and evaluated correlations between generated data and clinicopathological characteristics of the specimens.MethodsThe protein and mRNA expression was analyzed by Western blotting and real-time PCR, respectively, in tissue specimens of patients undergoing surgery for non-small cell lung cancer and soft tissue sarcomas. Association between expression of studied proteins and patient clinicopathological characteristics or outcome was evaluated.ResultsStomatin protein expression was down-regulated in 80% of NSCLC samples and this decrease significantly associated with presence of lymph node metastases. Flotillin-2 protein expression was up-regulated in the majority of NSCLC samples whereas caveolin-1α expression was decreased. We revealed a strong correlation between STOM and FLOT-1 mRNA expression in both pathologies, although the gene expression changes were diverse.ConclusionsOur data demonstrate for the first time that expression of stomatin, a poorly studied microdomain-forming protein, significantly changes in human tumors, thus pointing to its importance in the progression of NSCLC. We also suggest the existence of some relationship between the expression of these proteins.

MT1-MMP targeting to endolysosomes is mediated by upregulation of flotillins

“…Moreover, we provided the first demonstration of this correlation also in RMS, a sarcoma of skeletal muscle origin. The only previous study on sarcomas revealed increased FLOT1 mRNA expression in synovial sarcoma, fibrous histiocytoma and malignant schwannoma (Arkhipova et al, 2014). Using RMS cell lines, we demonstrated higher flotillin-1 and -2 expression in the cell lines derived from ARMS (the most invasive type) than in those derived from ERMS.…”

Decreased expression of stomatin predicts poor prognosis in HER2-positive breast cancer

“…Arkhipova’s and colleagues recently reported that down-regulation of stomatin mRNA was correlated with positive lymph node status in 48 patients [19]. In our study, we initially proposed that lipid-raft localized stomatin might be able to modulate the activity of the HER2-positive breast cancer.…”

“…Recently reported by Arkhipova and colleagues in 2014, stomatin is down-regulated in non-small cell lung cancer and is associated with lymph node metastases [19]. This is the first and the only one study to demonstrate that stomatin has a role in carcinogenesis.…”

Lipid rafts in immune signalling: current progress and future perspective

“…As shown in Fig. 2, [17][18][19][20][21][22][23][24][25][26][27][28][29] various molecules involved in disease progression have also been found to be associated with lipid rafts and caveolae.…”